Targets › CDK9
3 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when…. (UniProt, P50750)
Open in Phaseline: the race on CDK9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Dinaciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor | CDK1, CDK2, CDK5, CDK9 | Phase 2 | Acral Lentiginous Melanoma; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Sellas Life Sciences Group | SLS009 CDK9 inhibitor | CDK9 | Phase 1 | Hematologic Malignancies | Dec 2026 |
| National Cancer Institute (NCI) | Zotiraciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor | CDK1, CDK2, CDK7, CDK9, FLT3 | Phase 1 | Brain Tumor | Aug 2028 |
Brain Tumor (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1) Hematologic Malignancies (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.